Table 2. HAV and HEV markers among patients with acute hepatitis by age group, gender and study region.

			HAV			HEV
		Overall	Total Ig N (%)	IgM N (%)	RNA N (%)	IgG N (%)	IgM N	RNA N
Age group (years)	1–10	37	35 (94.6%)	14 (37.8%)	14 (37.8%)	2 (5.4%)	0	0
	11–20	20	19 (95.0%)	4 (20.0%)	3 (15.0%)	6 (30.0%)	0	0
	21–30	11	10 (90.9%)	2 (18.2%)	1 (9.1%)	3 (27.3%)	0	0
	31–40	15	15 (100%)	3 (20.0%)	2 (13.3%)	4 (26.7%)	0	0
	>40	9	9 (100%)	0	0	3 (33.3%)	0	0
Sex	Male	52	49 (94.2%)	14 (26.9%)	13 (25.0%)	9 (17.3%)	0	0
	Female	40	39 (97.5%)	9 (22.5%)	7 (17.5%)	9 (22.5%)	0	0
Study region	Gabes	25	24 (96.0%)	14 (56.0%)	13 (52.0%)	3 (12.0%)	0	0
	Medenine	40	39 (97.5%)	5 (12.5%)	5 (12.5%)	9 (22.5%)	0	0
	Tataouine	27	25 (92.6%)	4 (14.8%)	2 (7.4%)	6 (22.%)	0	0
Total		92	88 (95.6%)	23 (25.0%)	20 (21.7%)	18 (19.5%)	0	0